Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The RHA Collection is a family of injectable dermal fillers composed of resilient hyaluronic acid (RHA), designed specifically for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds. These fillers are formulated using a gentle manufacturing process that preserves the natural structure of hyaluronic acid, allowing them to more closely mimic the HA naturally found in human skin. This design enables the fillers to adapt to facial movements for a natural look both at rest and in motion. The collection includes several formulations—RHA 2, RHA 3, RHA 4, and RHA Redensity—each tailored for different depths and severities of wrinkles or volume loss. The mechanism involves providing structural support by supplementing lost or diminished hyaluronic acid in the skin’s dermal layers[3][5][6][7]. The product is FDA-approved for use in adults aged 22 years or older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHA Collection.